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ABSTRACT: 
 
Background Subclinical thyroid dysfunction, defined as thyroid-stimulating hormone (TSH) 
levels outside the reference range with normal free thyroxine levels in asymptomatic patients, is 
associated with alterations in cardiac hemodynamics. We used Mendelian randomization to 
assess the role of thyroid dysfunction for cardiovascular disease.  
Methods Single-nucleotide polymorphisms associated with thyroid function were identified 
from a genome-wide association meta-analysis in up to 72 167 individuals. Data for genetic 
associations with cardiovascular disease were obtained from meta-analyses of genome-wide 
association studies of atrial fibrillation (n=537 409 individuals), coronary artery disease 
(n=184 305 individuals), and ischemic stroke (n=438 847) as well as from the UK Biobank 
(n=367 703 individuals).  
Results Genetically predicted TSH levels and hyperthyroidism were statistically significantly 
associated with atrial fibrillation but no other cardiovascular diseases at the Bonferroni-corrected 
level of significance (P <7.810-4). The odds ratios of atrial fibrillation were 1.15 (95% 
confidence interval 1.11-1.19, P=2.410-14) per genetically predicted one standard deviation 
decrease in TSH levels and 1.05 (95% confidence interval 1.03-1.08, P=5.410-5) for genetic 
predisposition to hyperthyroidism. Genetically predicted free thyroxin levels were not 
statistically significantly associated with any cardiovascular disease. 
Conclusions: This Mendelian randomization study supports evidence for a causal association of 
decreased TSH levels in the direction of a mild form of hyperthyroidism with increased risk of 
atrial fibrillation but no other cardiovascular diseases. 
 
 
 
 
Keywords: atrial fibrillation; cardiovascular disease; hyperthyroidism; Mendelian 
randomization; thyrotropin 
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Subclinical thyroid dysfunction, defined as serum thyroid-stimulating hormone (TSH) levels 
below (hyperthyroidism) or above (hypothyroidism) the reference interval with normal free 
thyroxine (FT4) levels in asymptomatic patients,1 is a common condition and is particularly 
prevalent in older women.2-6 Subclinical thyroid dysfunction is associated with alterations in 
cardiac hemodynamics, such as impaired cardiac contractility, increased heart rate, systolic 
hypertension, increased left ventricular mass, and diastolic dysfunction.1,7-12  
Data from observational prospective studies on subclinical thyroid dysfunction in relation 
to risk of cardiovascular disease (CVD) are inconclusive. Subclinical hyperthyroidism was 
reported to be positively associated with risk of atrial fibrillation (AF),4,13-18 coronary heart 
disease,18,19 overall stroke,20 and heart failure5 in several studies. Subclinical hypothyroidism has 
been found to be associated with increased risk of coronary heart disease,3,21,22 heart failure5 and 
cardiac mortality3,21,22 but not with risk of AF or stroke.21 However, residual confounding or 
reverse causality may have affected those associations and may also explain the inconsistent 
results. 
Genetic variants with an explicit association with a potential risk factor (e.g., TSH levels) 
can be used as unbiased proxies for the risk factor to determine causality.23,24 This method, 
known as Mendelian randomization (MR), builds on Mendel’s second law and the fact that 
genetic variants are randomly distributed at conception and thus unlikely related to possible 
confounders. In addition, reverse causality is avoided because disease cannot affect genotype. 
Given the controversy regarding the role of thyroid dysfunction for CVD, we used the 
MR design to determine the associations of TSH levels and hyper- and hypothyroidism with 
CVD. Our primary aim was to assess the associations of TSH levels and hyper- and 
hypothyroidism with AF, coronary artery disease (CAD), and ischemic stroke using data from 
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meta-analyses of genome-wide association studies (GWAS) of these outcomes25-27 and data from 
the UK Biobank.28 In secondary analyses, we investigated the associations of TSH levels and 
hyper- and hypothyroidism with other CVD outcomes in UK Biobank. Finally, we examined 
whether there is an association between FT4 levels and any CVD outcome. 
 
METHODS 
The methods are available as supplemental material. This study is based on publicly available 
summary-level data, which are available in the supplemental material. All studies included in the 
analyses received ethics approval from a relevant institutional review board, and all participants 
had provided informed consent.  
 
RESULTS 
Genetic Consortia  
Analyses using data from three large-scale genetic consortia (Atrial Fibrillation Consortium 
[AFGen] 2018 GWAS dataset, Coronary ARtery DIsease Genome-wide Replication and Meta-
analysis plus The Coronary Artery Disease consortium’s 1000 Genomes-based GWAS 
[CARDIoGRAMplusC4D], and MEGASTROKE) revealed a statistical significant association 
between genetically decreased TSH levels and higher odds of AF (odds ratio [OR] 1.15, 95% 
confidence interval [CI] 1.11-1.19, P=2.410-14) but not CAD or ischemic stroke as a whole 
(Figure 1). Among ischemic stroke subtypes, genetically decreased TSH levels were associated 
with higher odds of cardioembolic stroke (OR 1.11, 95% CI 1.02-1.22, P=0.02) (Figure 1) but 
the association did not achieve statistical significance at the Bonferroni-corrected threshold. 
Hyperthyroidism was associated with higher odds of AF (OR 1.05, 95% CI 1.03-1.08, P=5.410-
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5), whereas hypothyroidism was associated with lower odds of AF (OR 0.95, 95% CI 0.92-0.98, 
P=8.010-4) (Figure 1). Genetically higher FT4 levels were not associated with any outcome 
(Figure 1).  
Results for AF were similar when using data from the AFGen 2017 GWAS dataset. 
In these analyses, the ORs were 1.16 (95% CI 1.10-1.23, P=7.110-7) per one SD decrease of 
TSH levels, 1.05 (95% CI 1.01-1.09, P=0.02) for hyperthyroidism, 0.94 (95% CI 0.89-0.99, 
P=0.01) for hypothyroidism, and 1.00 (95% CI 0.92-1.09, P=0.93) per one SD increase of FT4 
levels. 
UK Biobank  
In the UK Biobank, genetically decreased TSH levels were statistically significantly associated 
with higher odds of AF (OR 1.20, 95% CI 1.13-1.27, P=1.410-9) but not the other outcomes 
(Table 1). There was suggestive evidence of associations between hyperthyroidism and higher 
odds of AF and lower odds of thoracic aortic aneurysm; hypothyroidism and higher odds CAD 
and hypertension; and increased FT4 levels and higher odds of peripheral arterial disease (Table 
1).  
Sensitivity Analyses 
The associations of TSH and FT4 levels with the outcomes were robust when limiting the 
analysis to the lead SNP of each locus (Table S5). When excluding the three loci associated with 
both hyper- and hypothyroidism, the ORs of AF (using data from 2018 AFGen GWAS) were 
1.07 (95% CI 1.04-1.11, P=3.610-5) for hyperthyroidism and 0.99 (95% CI 0.95-1.03, P=0.59) 
for hypothyroidism. The results for TSH levels using the weighted median and MR-Egger 
approaches were similar to those of the primary analysis (inverse-variance weighted method), 
but the precision of the estimates was as expected lower (Table S6). The MR-Egger analysis 
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provided no evidence of directional pleiotropy (Table S6). The MR-PRESSO analysis identified 
no outlying single-nucleotide polymorphisms (SNPs) in the analysis of TSH levels and AF. 
However, there was one outlying SNP in the analyses of TSH levels in relation to CAD and 
aortic valve stenosis and three outlying SNPs in the analyses of TSH and hypertension (Table 
S7). Exclusion of those SNPs did not change the results appreciably (Table S7). Likewise, 
inclusion of the pleiotropic SNP in the ABO gene did not change the interpretation of the results 
for TSH levels and any CVD outcome (Table S8).  
 
DISCUSSION 
For the first time, this study uses a MR approach to systematically investigate the relationship of 
thyroid function and dysfunction with a wide range of CVD outcomes. Our results showed that 
genetically decreased TSH levels and hyperthyroidism were robustly associated with higher odds 
of AF. We found no statistically significant and consistent associations of TSH levels, hyper- or 
hypothyroidism, or FT4 levels with the other CVD outcomes, though there was suggestive 
evidence of possible associations between decreased TSH levels and higher odds of 
cardioembolic stroke, hyperthyroidism and lower odds of thoracic aortic aneurysm, 
hypothyroidism and higher odds AF, CAD and hypertension, and increased FT4 levels and 
higher odds of peripheral arterial disease. However, those suggestive associations were only 
observed in one dataset (one of the genetic consortia or UK Biobank) or were not consistent in 
sensitivity analyses.  
Our findings support prior observational studies associating decreased TSH levels and 
hyperthyroidism to increased risk of AF4,13-17 as well as results from two recent MR studies 
associating genetically higher TSH levels to decreased risk of AF.29,30 However, an individual 
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patient data analysis of 30 085 participants (including 2574 AF cases) from 11 cohorts showed 
only a suggestive association of lower TSH levels within the reference range with increased risk 
of AF (P for linear trend = 0.054).31 That analysis further showed that FT4 levels were positively 
associated with AF risk in euthyroid individuals.31 A positive association between genetically 
higher FT4 levels and AF was not detected in the present MR analysis, but we were unable to 
simultaneously control for TSH levels. In addition, these MR results reflect the association 
between lifelong higher FT4 levels on AF risk and it is unknown whether high FT4 levels during 
different periods in the life course differently affect the risk of developing AF. 
An association between decreased TSH levels and increased risk of AF may in part be 
mediated by increased left ventricular mass8,10-12 and diastolic dysfunction,7 both of which are 
associated with an increased risk of AF,32,33 though the causal relationships remain unclear. 
Findings from an experimental study in mice showed that hyperthyroidism, with suppression of 
circulating TSH levels, leads to impaired Pitx2>Wnt>microRNA signaling,34 thus providing a 
molecular link between hyperthyroidism and AF since PITX2 is one of the strongest genetic 
locus related to AF.25 
A chief strength of this study is the MR approach, which reduces systematic biases (e.g., 
confounding and reverse causality) that can distort the results of conventional observational 
studies. Another major strength is that we examined the associations of thyroid function and 
dysfunction with AF, CAD and ischemic stroke using data from large-scale genetic consortia, 
which included a large number of cases. Hence, we had high statistical power to detect weak 
associations of the examined exposures and those outcomes. However, the power was low in the 
analyses of several CVD outcomes measured in UK Biobank, in particular intracerebral and 
subarachnoid hemorrhage, abdominal and thoracic aortic aneurysm, and aortic valve stenosis. 
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We thus cannot rule out that the lack of association with those outcomes are due to insufficient 
power. We could restrict the study populations (except in the CARDIoGRAMplusC4D 
consortium) to individuals of European ancestry, a constraint that reduced bias from population 
stratification. A limitation of any MR analysis is that pleiotropy cannot be ruled out as an 
explanation for an observed association. Nevertheless, we found no evidence that directional 
pleiotropy may have influenced the results. A further shortcoming is that we could not examine 
U-shaped associations or effects of very low or high TSH and FT4 levels or different 
combinations of TSH and FT4 levels on CVD risk. 
CONCLUSIONS 
This MR study supports evidence for a causal association between decreased TSH levels in the 
direction of a mild form of hyperthyroidism and increased risk of AF. Suggestive evidence of 
possible associations was found between thyroid dysfunction and some other CVD outcomes, 
including cardioembolic stroke. These findings may have clinical implications because they 
suggest that treatment of subclinical hyperthyroidism may be a complement to other possible 
prevention strategies for AF, such as reducing excessive alcohol consumption, tobacco control, 
reducing blood pressure, blood glucose, and body mass, and therapy for myocardial infarction 
and heart failure.35 
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Table 1. Associations of genetically predicted decreased TSH levels, hyperthyroidism, hypothyroidism, and increased FT4 levels with 
odds ratio of 13 cardiovascular diseases in UK Biobank  
 
  TSH levels  Hyperthyroidism  Hypothyroidism  FT4 levels 
Outcome Cases* OR (95% CI)† P   OR (95% CI)† P   OR (95% CI)† P   OR (95% CI)† P  
Atrial fibrillation  13 538 1.20 (1.13-1.27) 1.410-9  1.06 (1.02-1.10) 0.005  0.95 (0.90-1.01) 0.11  0.97 (0.90-1.05) 0.47 
Coronary artery disease  24 531 1.00 (0.96-1.05) 0.91  0.99 (0.96-1.02) 0.40  1.06 (1.02-1.11) 0.008  0.99 (0.93-1.05) 0.63 
Ischemic stroke 3554 1.02 (0.91-1.14) 0.75  1.03 (0.95-1.11) 0.51  1.10 (0.99-1.22) 0.09  1.01 (0.87-1.17) 0.91 
Intracerebral hemorrhage 1655 0.99 (0.84-1.17) 0.91  1.04 (0.93-1.17) 0.47  0.99 (0.84-1.16) 0.89  1.03 (0.83-1.28) 0.81 
Subarachnoid hemorrhage 1834 1.06 (0.91-1.24) 0.44  1.08 (0.97-1.20) 0.17  0.92 (0.79-1.07) 0.28  1.10 (0.89-1.36) 0.36 
Heart failure 4803 1.02 (0.92-1.12) 0.71  0.98 (0.91-1.04) 0.46  1.04 (0.95-1.14) 0.41  1.01 (0.89-1.15) 0.91 
Aortic valve stenosis 1252 1.01 (0.99-1.04) 0.35  1.01 (0.99-1.03) 0.18  1.00 (0.97-1.02) 0.84  1.01 (0.98-1.05) 0.51 
Abdominal aortic aneurysm 758 0.90 (0.71-1.15) 0.41  1.02 (0.86-1.20) 0.84  0.86 (0.68-1.08) 0.20  1.05 (0.76-1.46) 0.75 
Thoracic aortic aneurysm 231 0.65 (0.42-1.01) 0.06  0.60 (0.44-0.81) 0.001  1.47 (0.97-2.23) 0.07  0.64 (0.36-1.13) 0.13 
Deep vein thrombosis 3514 1.07 (1.00-1.15) 0.05  1.00 (0.95-1.05) 0.93  1.04 (0.97-1.11) 0.28  0.98 (0.89-1.08) 0.65 
Pulmonary embolism 8891 1.09 (0.99-1.20) 0.07  1.03 (0.96-1.10) 0.39  1.06 (0.96-1.16) 0.23  0.94 (0.83-1.06) 0.31 
Peripheral arterial disease 5097 1.06 (0.94-1.18) 0.34  0.99 (0.92-1.07) 0.86  1.06 (0.95-1.18) 0.33  0.83 (0.71-0.96) 0.01 
Hypertension 119 500 1.01 (0.98-1.03) 0.66  1.01 (1.00-1.03) 0.14  1.04 (1.01-1.06) 0.003  0.99 (0.96-1.02) 0.65 
 
*Total number of participants is 367 703. 
†Odds ratios are expressed per one SD decrease of TSH levels, per one unit higher log-odds of hyperthyroidism and hypothyroidism, and per one SD increase of 
FT4 levels. Hyperthyroidism = TSH levels below the reference range in the population; hypothyroidism = TSH levels above the reference range in the population. 
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Figure Legend: 
 
Figure 1. Associations of genetically decreased TSH levels, hyperthyroidism, hypothyroidism 
and increased FT4 levels with odds ratio of AF, CAD, and ischemic stroke and its subtypes 
based on data from the AFGen, CARDIoGRAMplusC4D and MEGASTROKE consortia. Odds 
ratios are expressed per one SD decrease of TSH levels, per one unit higher log-odds of 
hyperthyroidism and hypothyroidism and per one SD increase of FT4 levels. Hyperthyroidism = 
TSH levels below the reference range in the population; hypothyroidism = TSH levels above the 
reference range in the population. 
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